Israeli Company Galmed Gets Positive Trial Results for Liver Drug Israeli Company Galmed Gets Positive Trial Results for Liver Drug
Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for non-alcoholic steatohepatitis (NASH), a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.Reuters Health Information
Obesity is a significant health problem and is on the rise in today's society. As obesity rises, so do associated comorbidities, which include non-alcoholic fatty liver disease (NAFLD) . Studies have found that as body mass index (BMI) increases, so does the prevalence of NAFLD . In obese individuals undergoing bariatric surgery, NAFLD is seen in 75-100% of cases . NAFLD includes a spectrum of liver abnormalities, which ranges from benign simple steatosis (SS) to non-alcoholic steatohepatitis (NASH), which in some cases progresses to hepatic cirrhosis .
CONCLUSION: Type 2 diabetes mellitus plays an important role in the progression of non-alcoholic fatty liver disease as an independent risk factor for severe fibrosis. PMID: 29893699 [PubMed - in process]
CONCLUSION: Patients with non-alcoholic fatty liver disease showed elevated levels of circulating Hb, evidence that suggests that Hb exerts a protective role, as it may act as an antioxidant and may counteract the adverse effects of this disease. PMID: 29893698 [PubMed - in process]
Authors: Dwyer AA, Quinton R Abstract The metabolic syndrome (MetS) is a term used to describe the constellation of cardiometabolic risk factors including central adiposity, dyslipidemia, insulin resistance, non-alcoholic fatty liver disease and arterial hypertension. Notably, a number of studies have shown high rates of testosterone (T) deficiency in men with MetS and type 2 diabetes mellitus (T2DM). Both hypogonadism and MetS confer increased health risk for morbidity and mortality as men with the MetS are at twice the risk for developing cardiovascular disease and at 5-fold higher risk for developing T2DM. Moreo...
Publication date: August 2018 Source:Journal of Functional Foods, Volume 47 Author(s): Misung Kwon, Su-Jin Lim, Eun-Ji Joung, Bonggi Lee, Chul-Woong Oh, Hyeung-Rak Kim Sargassum serratifolium has diverse health-promoting effects because of high levels of meroterpenoids with strong antioxidant and anti-inflammatory activities. Here, we investigated the effects of a meroterpenoid-rich fraction of an ethanolic extract of S. serratifolium (MES) on obesity and obesity-related hepatic steatosis in high fat (HF)-fed C57BL/6J mice. MES supplementation markedly reduced HF diet-induced obesity and hepatic steatosis without changes ...
Conclusion Lifestyle intervention effectively targeted obesity and the metabolic syndrome. Liver steatosis, damage and fibrosis were ameliorated in this real-life cohort of morbidly obese patients - mediated, in part, by changes in the adipokine profile. Patients with weight loss of >10% seemed to benefit most. PMID: 29878845 [PubMed - as supplied by publisher]
We recently showed that plasma cholesteryl ester transfer protein (CETP) is mainly derived from VSIG4-positive Kupffer cells. Activation of these cells by the bacterial endotoxin lipopolysaccharide (LPS) strongly decreases CETP expression. As Kupffer cell activation plays a detrimental role in the progression of non-alcoholic fatty liver disease (NAFLD), we aimed to study if metabolic liver inflammation is also associated with a decrease in hepatic and circulating CETP.
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease globally [1 –3]. This condition is characterized by excess liver fat in the absence of other causes such as alcohol consumption [4,5]. Obesity, type 2 diabetes mellitus (DM) and metabolic syndrome (MetS) are consistently identified as the most important risk factors for NAFLD [4,6].
Non-alcoholic fatty liver disease (NAFLD) is characterized by abnormal fat accumulation in liver cells and is the most common chronic liver disease worldwide [1, 2]. It is closely associated with obesity and is one of the important etiologies of hepatocellular carcinoma (HCC) and liver failure . The development process of NAFLD can start from simple steatosis (NAFLD) to non-alcoholic steatohepatitis (NASH) and finally leads to cirrhosis and HCC in the absence of excessive alcohol intake [3, 4].
Non-alcoholic fatty liver disease (NAFLD) is common both in obese and overweight patients. Fibroblast growth factor 19 (FGF19), an intestinal hormone, could play a role in the complex pathogenesis of NAFLD. Th...